NasdaqCM:CLDXBiotechs
Celldex Data At 2026 EAACI Puts Mast Cell Pipeline In Focus
Celldex Therapeutics (NasdaqCM:CLDX) plans to present new clinical results for barzolvolimab in chronic and cold urticaria at the 2026 European Academy of Allergy and Clinical Immunology Congress.
The company will also share first in human Phase 1 data for CDX-622, targeting KIT signaling in mast cells.
These data represent fresh updates on Celldex’s core pipeline that have not been covered in earlier reports.
Celldex enters this data update with its stock at $29.96 and a return of 47.2%...